Inflammasomes in Atherosclerosis—From Pathophysiology to Treatment
Pharmaceuticals · 28.08.2023 · 16 (9) · 1211
DOI: 10.3390/ph16091211 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 28.08.2023. Verfasst von Panagiotis Theofilis und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1st Department of Cardiology, "Hippokration" General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Atherosclerosis, a chronic inflammatory disease characterized by arterial plaque accumulation, remains a significant global health challenge. In recent years, inflammasomes, the intracellular multiprotein complexes crucial for initiating innate immune responses, have emerged as key players in atherosclerosis pathophysiology. This review article aims to provide a comprehensive overview of the current understanding of inflammasome activation and its impact on atherosclerosis development and progression. We explore the intricate interplay between traditional cardiovascular risk factors and inflammasome activation, leading to the perpetuation of inflammatory cascades that drive plaque formation and instability. The review focuses on the molecular mechanisms underlying inflammasome activation, including the role of pattern recognition receptors and cytokines in this process. Moreover, we discuss the contribution of inflammasomes to endothelial dysfunction, foam cell formation, and vascular inflammation. Additionally, recent advances in therapeutic strategies targeting inflammasomes are examined, including pharmacological agents and potential immunomodulatory approaches. By collating and analyzing the current evidence, this review provides valuable insights into the potential of inflammasome-targeted therapies for atherosclerosis management and treatment. Understanding the pivotal role of inflammasomes in atherosclerosis pathophysiology offers promising prospects for developing effective and personalized therapeutic interventions that can mitigate the burden of this prevalent cardiovascular disorder and improve patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 1st Department of Cardiology, "Hippokration" General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- 3rd Department of Cardiology, Thoracic Diseases General Hospital "Sotiria", National and Kapodistrian University of Athens, 11527 Athens, Greece.
- Department of Cardiology, General Hospital of Corinth, 20100 Corinth, Greece.
ORCID-Profile: Panagiotis Theofilis, Evangelos Oikonomou
Zitieren
APA
Theofilis, P., Oikonomou, E., Chasikidis, C., Tsioufis, K., & Tousoulis, D. (2023). Inflammasomes in Atherosclerosis—From Pathophysiology to Treatment. Pharmaceuticals, 16(9), 1211. https://doi.org/10.3390/ph16091211
Vancouver
Theofilis P, Oikonomou E, Chasikidis C, Tsioufis K, Tousoulis D. Inflammasomes in Atherosclerosis—From Pathophysiology to Treatment. Pharmaceuticals. 2023;16(9):1211. doi:10.3390/ph16091211
BibTeX
@article{Theofilis2023,
author = {Theofilis, Panagiotis and Oikonomou, Evangelos and Chasikidis, Christos and Tsioufis, Konstantinos and Tousoulis, Dimitris},
title = {Inflammasomes in Atherosclerosis—From Pathophysiology to Treatment},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {9},
pages = {1211},
doi = {10.3390/ph16091211}
}
EUVIMED